Carbamazepine Intravenous and Ledipasvir and sofosbuvir
Determining the interaction of Carbamazepine Intravenous and Ledipasvir and sofosbuvir and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using sofosbuvir together with carBAMazepine is not recommended. Combining these medications may significantly reduce the blood levels of sofosbuvir, which may make the medication less effective in treating hepatitis C. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given with sofosbuvir in fixed-dose combination products such as ledipasvir and velpatasvir. Induction of P-gp-mediated efflux in the intestine decreases the oral bioavailability of these antiviral agents, which are substrates of the transporter. The interaction has been studied with rifampin, a potent inducer of P-gp and CYP450 isoenzymes. In 17 healthy volunteers, administration of a single 400 mg dose of sofosbuvir during multiple dosing of rifampin 600 mg once daily reduced mean sofosbuvir peak plasma concentration (Cmax) and systemic exposure (AUC) by 77% and 72%, respectively. Likewise, administration of a single 90 mg dose of ledipasvir to 31 healthy volunteers during multiple dosing of rifampin 600 mg once daily decreased mean ledipasvir Cmax and AUC by 35% and 59%, respectively. When a single 100 mg dose of velpatasvir was given with rifampin 600 mg once daily to 12 healthy volunteers, velpatasvir Cmax decreased by 71% and AUC decreased by 82%.
MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of potent P-gp inducers should generally be avoided during treatment with sofosbuvir, given either as a single-ingredient product or as a fixed-dose combination product with ledipasvir or velpatasvir.
- "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences, Foster City, CA.
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences, Foster City, CA.
- "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences, Foster City, CA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: carbamazepine
Brand name: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR
Synonyms: Carbamazepine, CarBAMazepine
Generic Name: ledipasvir / sofosbuvir
Brand name: Harvoni
Synonyms: Ledipasvir and Sofosbuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Carbamazepine Intravenous-Ledipasvir and Sofosbuvir Tablets
- Carbamazepine Intravenous-Leena
- Carbamazepine Intravenous-Lefamulin
- Carbamazepine Intravenous-Lefamulin Acetate
- Carbamazepine Intravenous-Lefamulin Injection
- Carbamazepine Intravenous-Lefamulin Tablets
- Ledipasvir and sofosbuvir-Carbamazepine Oral Suspension
- Ledipasvir and sofosbuvir-Carbamazepine Tablets
- Ledipasvir and sofosbuvir-Carbaphen 12
- Ledipasvir and sofosbuvir-Carbaphen CH
- Ledipasvir and sofosbuvir-Carbaphen Ped CH
- Ledipasvir and sofosbuvir-Carbastat